Detalhe da pesquisa
1.
bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease.
Ann Rheum Dis
; 2024 Apr 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38653531
2.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36708469
3.
Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Blood
; 135(18): 1517-1530, 2020 04 30.
Artigo
Inglês
| MEDLINE | ID: mdl-32107537
4.
Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Br J Haematol
; 195(2): 230-243, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34341985
5.
Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data.
Ann Hematol
; 100(8): 2087-2093, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33270162
6.
Prognosis and Staging of AL Amyloidosis.
Acta Haematol
; 143(4): 388-400, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32570242
7.
Development and Validation of Staging Systems for AA Amyloidosis.
J Am Soc Nephrol
; 35(6): 782-794, 2024 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38512269
8.
AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis.
Blood
; 130(5): 632-642, 2017 08 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28550043
9.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Blood
; 130(5): 597-605, 2017 08 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28550039
10.
Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.
Haematologica
; 104(7): 1451-1459, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-30655373
11.
Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
Blood
; 128(4): 594-602, 2016 07 28.
Artigo
Inglês
| MEDLINE | ID: mdl-27257181
12.
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.
Haematologica
; 103(3): 514-521, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29217776
13.
Submyeloablative total body irradiation-based conditioning and allogeneic stem cell transplantation in high-risk myeloma with early progression after up-front autologous transplantation.
Br J Haematol
; 196(1): 244-248, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34431093
14.
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Br J Haematol
; 178(4): 521-533, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28589551
15.
Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.
Haematologica
; 102(7): 1281-1290, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28341732
16.
Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Haematologica
; 102(8): 1424-1431, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28522573
17.
Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21.
Am J Hematol
; 96(7): E253-E257, 2021 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33844864
18.
In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.
Brain
; 138(Pt 3): 549-62, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25526974
19.
First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival.
Blood
; 131(3): 368-371, 2018 01 18.
Artigo
Inglês
| MEDLINE | ID: mdl-29180400
20.
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
Blood
; 121(17): 3420-7, 2013 Apr 25.
Artigo
Inglês
| MEDLINE | ID: mdl-23479568